TEGNA Announces Quarterly Dividend
TYSONS, Va.–(BUSINESS WIRE)–TEGNA Inc.’s (NYSE: TGNA) Board of Directors declared a regular quarterly dividend of…
News
CORRECTION: Orion Group Interim Report 1–3/2022
ORION CORPORATION INTERIM REPORT 1–3/2022 28 APRIL 2022 at 16:00 EEST CORRECTION: Orion Group Interim Report 1–3/2022 This…
Scilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO)
SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Scilex Holding Company…
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France…
Mountain Valley MD Holdings Provides Business Update
TORONTO, April 28, 2022 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON and PHOENIX, April 28, 2022 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTCQB: ACUT), a…
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ:…
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
New Position Aimed at Attracting, Retaining, and Cultivating a Best-in-Class Workforce as Allogene Scales its…
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical…
Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress
Follow up ILUVIEN® PALADIN data to be presented onsite at the annual Association for Research…
T2 Biosystems Announces Formation and Members of Scientific Advisory Board
LEXINGTON, Mass., April 28, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th
MIAMI, April 28, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today…
Neuronetics to Report First Quarter 2022 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 28, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity,…
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…
Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis
Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the…
Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”…
Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…
Motus GI to Release First Quarter Results and Provide a Business Update on May 12
FORT LAUDERDALE, Fla., April 28, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS)…
Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting
Based on positive feedback provided by FDA on key clinical design details Jasper plans to…